I have been having my ctDNA measured since 2014 when I entered a clinical trial and had the additional opportunity to provide samples for a study to monitor for minimal residual disease. The clinical trial was successful and I continue to have ctDNA measurements done on a quarterly basis. ctDNA has been around for some time having been introduced for monitoring minimal residual disease in lymphomas and leukemias. It is now moving in to solid tumor monitoring after technical hurdles were overcome and is being adopted by GI oncologists for monitoring colon cancer. It is being evaluated for pancreatic tumors and there is a working group at ASCO (American Society of Clinical Oncologists) evaluating studies addressing false positive and negative results. It is a matter of time when ctDNA for pancreatic cancer surveillance will become accepted and a standard for more sensitive monitoring. In the meantime, I m pleased that I am able to take advantage of this additional surveillance technology that is significantly more sensitive than current imaging techniques.